CA2383298A1 - Nouveaux derives d'.alpha.-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent - Google Patents
Nouveaux derives d'.alpha.-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent Download PDFInfo
- Publication number
- CA2383298A1 CA2383298A1 CA002383298A CA2383298A CA2383298A1 CA 2383298 A1 CA2383298 A1 CA 2383298A1 CA 002383298 A CA002383298 A CA 002383298A CA 2383298 A CA2383298 A CA 2383298A CA 2383298 A1 CA2383298 A1 CA 2383298A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- amino acids
- nitro
- formula
- contain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
L'invention concerne de nouveaux composés répondant à la formule (I) (voir formule I) dans laquelle (voir formule II) représente un hétérocycle à 5 chaînons; Ak représente une chaîne alkylène ; X représente une liaison simple ou un groupement phényl~;ne ; R1 et R2, identiques ou différents, représentent chacun un atome d'hydrogène ou un groupement alkyle ; Y représente un groupement CHNO2 ou NR4 dans lequel R4 représente un atome d'hydrogène ou un groupement alkyle ; et R1 représente soit un groupement alkyle, nitro ou cyano, lorsque Y représente CHNO2, soit un groupement nitro ou cyano, lorsque Y représente NR4 ; sous réserve que , lorsque (voir formule III) représente un hétérocycl e azoté à 5 chaînons non substitués, Ak représente un groupement -(CH2)3-, X représente une liaison simple et Y représente NH, R3 ne peut représenter un groupement nitro. L'invention vise également des tautomères et isomères optiques des composés de formule (I), ainsi que leurs sels d'addition à un acide pharmaceutiquement acceptable. Les composés selon l'invention sont utiles en tant qu'inhibiteurs de dipeptidyl-peptidase IV, dans le traitement de l'intolérance au glucose et des maladies associées à l'hyperglycémie.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0106375A FR2824825B1 (fr) | 2001-05-15 | 2001-05-15 | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR01.06375 | 2001-05-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2383298A1 true CA2383298A1 (fr) | 2002-11-15 |
CA2383298C CA2383298C (fr) | 2008-01-29 |
Family
ID=8863284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002383298A Expired - Fee Related CA2383298C (fr) | 2001-05-15 | 2002-05-10 | Nouveaux derives d'.alpha.-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Country Status (25)
Country | Link |
---|---|
US (1) | US6706742B2 (fr) |
EP (1) | EP1258476B1 (fr) |
JP (1) | JP3798337B2 (fr) |
KR (1) | KR100460782B1 (fr) |
CN (1) | CN1164573C (fr) |
AR (1) | AR033735A1 (fr) |
AT (1) | ATE331705T1 (fr) |
AU (1) | AU780480B2 (fr) |
BR (1) | BR0201697A (fr) |
CA (1) | CA2383298C (fr) |
CY (1) | CY1105385T1 (fr) |
DE (1) | DE60212759T2 (fr) |
DK (1) | DK1258476T3 (fr) |
EA (1) | EA004865B1 (fr) |
ES (1) | ES2266422T3 (fr) |
FR (1) | FR2824825B1 (fr) |
HK (1) | HK1050526A1 (fr) |
HU (1) | HUP0201646A3 (fr) |
MX (1) | MXPA02004642A (fr) |
NO (1) | NO322569B1 (fr) |
NZ (1) | NZ518948A (fr) |
PL (1) | PL353910A1 (fr) |
PT (1) | PT1258476E (fr) |
SI (1) | SI1258476T1 (fr) |
ZA (1) | ZA200203867B (fr) |
Families Citing this family (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
JP4494212B2 (ja) | 2002-11-12 | 2010-06-30 | メルク・シャープ・エンド・ドーム・コーポレイション | アルツハイマー病の治療用フェニルカルボキサミドベータセクレターゼ阻害剤 |
US7309714B2 (en) * | 2002-12-04 | 2007-12-18 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
CA2518465A1 (fr) * | 2003-03-25 | 2004-10-14 | Takeda San Diego, Inc. | Inhibiteurs de dipeptidyle peptidase |
WO2004098591A2 (fr) | 2003-05-05 | 2004-11-18 | Probiodrug Ag | Inhibiteurs de glutaminyl-cyclase |
WO2004103993A1 (fr) | 2003-05-14 | 2004-12-02 | Syrrx, Inc. | Inhibiteurs de dipeptidyl peptidase |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
KR20060041309A (ko) * | 2003-08-13 | 2006-05-11 | 다케다 야쿠힌 고교 가부시키가이샤 | 4-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도 |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2005026148A1 (fr) * | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Inhibiteurs de la dipeptidylpeptidase |
JP2007513058A (ja) * | 2003-09-08 | 2007-05-24 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
AU2004274309B2 (en) | 2003-09-22 | 2010-04-08 | Msd K.K. | Novel piperidine derivative |
CN1905876B (zh) | 2003-11-17 | 2010-06-09 | 诺瓦提斯公司 | 二肽基肽酶iv抑制剂的用途 |
WO2005058849A1 (fr) * | 2003-12-15 | 2005-06-30 | Glenmark Pharmaceuticals Ltd. | Nouveaux inhibiteurs de dipeptidyle peptidase iv, leur procede de preparation et compositions les contenant |
CN101618216B (zh) * | 2004-01-20 | 2012-01-04 | 诺瓦提斯公司 | 直接压片配方和方法 |
DK1715893T3 (da) * | 2004-01-20 | 2009-11-09 | Novartis Pharma Ag | Direkte kompressionsformulering og fremgangsmåde |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CN102134231B (zh) * | 2004-03-15 | 2020-08-04 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
CA2560314A1 (fr) | 2004-03-29 | 2005-10-20 | Merck & Co., Inc. | Utilisation de diaryltriazoles comme inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase-1 |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
FR2870538B1 (fr) * | 2004-05-19 | 2006-07-14 | Servier Lab | Nouveaux derives de pyrrolidines et de thiazolidines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JP2008501714A (ja) * | 2004-06-04 | 2008-01-24 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
WO2006019965A2 (fr) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Inhibiteurs de la dipeptidyl peptidase |
US7842707B2 (en) * | 2004-07-23 | 2010-11-30 | Nuada, Llc | Peptidase inhibitors |
ATE472531T1 (de) | 2004-08-06 | 2010-07-15 | Merck Sharp & Dohme | Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1 |
MX2007004305A (es) | 2004-10-12 | 2007-06-18 | Glenmark Pharmaceuticals Sa | Inhibidores novedosos de dipeptidil peptidasa iv, composiciones farmaceuticas que los contienen y procedimientos para su preparacion. |
US7872124B2 (en) * | 2004-12-21 | 2011-01-18 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
CA2600570C (fr) * | 2005-03-14 | 2011-12-06 | Transtech Pharma, Inc. | Derives de benzazole, compositions et methodes d'utilisation des derives comme inhibiteurs de la .beta.-secretase |
BRPI0608469A2 (pt) * | 2005-04-22 | 2010-01-05 | Alantos Pharmaceuticals Holding Inc | inibidores de dipeptidil peptidase-iv |
CA2609388C (fr) | 2005-05-30 | 2013-08-06 | Banyu Pharmaceutical Co., Ltd. | Nouveau derive de piperidine |
MY152185A (en) | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
AU2006277253A1 (en) | 2005-08-10 | 2007-02-15 | Msd K.K. | Pyridone compound |
WO2007017423A2 (fr) * | 2005-08-11 | 2007-02-15 | F. Hoffmann-La Roche Ag | Composition pharmaceutique |
EP1921065B1 (fr) | 2005-08-24 | 2010-10-20 | Banyu Pharmaceutical Co., Ltd. | Dérivé phénylpyridone |
EP1939194A4 (fr) | 2005-09-07 | 2010-12-08 | Banyu Pharma Co Ltd | Dérivé de pyridone substitué aromatique bicylique |
BRPI0616077B8 (pt) * | 2005-09-14 | 2021-05-25 | Takeda Pharmaceuticals Co | composição farmacêutica formulada em uma dose única, kit, artigo de manufatura, uso da composição farmacêutica e uso de um ou mais compostos antidiabéticos |
ATE532518T1 (de) * | 2005-09-14 | 2011-11-15 | Takeda Pharmaceutical | Dipeptidyl-peptidase-hemmer zur behandlung von diabetes |
TW200745079A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
CA2622642C (fr) * | 2005-09-16 | 2013-12-31 | Takeda Pharmaceutical Company Limited | Inhibiteurs de dipeptidylpeptidase |
TW200745080A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor |
JOP20180109A1 (ar) * | 2005-09-29 | 2019-01-30 | Novartis Ag | تركيبة جديدة |
EP1940842B1 (fr) | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Dérivés acylés de spiropipéridine en tant que modulateurs du récepteur de la mélanocortine-4 |
EP1944301A4 (fr) | 2005-10-27 | 2012-01-04 | Msd Kk | Nouveau derive de benzoxathiine |
RU2428423C2 (ru) | 2005-11-10 | 2011-09-10 | Баниу Фармасьютикал Ко., Лтд. | Азазамещенные спиропроизводные |
EP1801098A1 (fr) | 2005-12-16 | 2007-06-27 | Merck Sante | Dérivés de 2-Adamantylurea comme inhibiteurs de 11B-HSD1 |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
EP1999108A1 (fr) * | 2006-03-28 | 2008-12-10 | Takeda Pharmaceutical Company Limited | Préparation de dichlorhydrate de (r)-3-aminopipéridine |
WO2007112347A1 (fr) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Inhibiteurs de la dipeptidyl peptidase |
CN101421618B (zh) | 2006-04-11 | 2013-11-20 | 艾尼纳制药公司 | 使用gpr119受体鉴定可用于增加个体骨质量的化合物的方法 |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
KR20090004950A (ko) | 2006-04-12 | 2009-01-12 | 프로비오드룩 아게 | 효소 억제제 |
MX2009002772A (es) * | 2006-09-13 | 2009-05-28 | Takeda Pharmaceutical | Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro- 2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo. |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
JP5489333B2 (ja) | 2006-09-22 | 2014-05-14 | メルク・シャープ・アンド・ドーム・コーポレーション | 脂肪酸合成阻害剤を用いた治療の方法 |
AU2007301126A1 (en) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
WO2008055945A1 (fr) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies |
TW200838536A (en) * | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
EP1935420A1 (fr) | 2006-12-21 | 2008-06-25 | Merck Sante | Dérivés du 2-adamantyl-butyramide en tant qu'inhibiteurs selectifs de la 11beta-HSD1 |
KR100848491B1 (ko) * | 2007-01-16 | 2008-07-28 | 영진약품공업주식회사 | 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법 |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
WO2008120653A1 (fr) | 2007-04-02 | 2008-10-09 | Banyu Pharmaceutical Co., Ltd. | Dérivé d'indoledione |
JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
WO2008137105A1 (fr) | 2007-05-07 | 2008-11-13 | Merck & Co., Inc. | Procédé de traitement à l'aide de composés aromatiques fusionnés ayant une activité anti-diabétique |
EP2527360B1 (fr) | 2007-06-04 | 2015-10-28 | Synergy Pharmaceuticals Inc. | Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
AU2009220605A1 (en) | 2008-03-06 | 2009-09-11 | Msd K.K. | Alkylaminopyridine derivative |
AU2009229860A1 (en) | 2008-03-28 | 2009-10-01 | Msd K.K. | Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |
EP2108960A1 (fr) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Procédés d'utilisation d'un récepteur couplé à protéine G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement des conditions modulées de secrétagogues BY (PYY) et composés utiles dans le traitement des conditions par PYY |
EP2110374A1 (fr) | 2008-04-18 | 2009-10-21 | Merck Sante | Dérivés de benzofurane, benzothiophène, benzothiazol en tant que modulateurs FXR |
ES2627848T3 (es) | 2008-06-04 | 2017-07-31 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
JPWO2009154132A1 (ja) | 2008-06-19 | 2011-12-01 | Msd株式会社 | スピロジアミン−ジアリールケトオキシム誘導体 |
WO2010009319A2 (fr) | 2008-07-16 | 2010-01-21 | Synergy Pharmaceuticals Inc. | Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres |
EP2319841A1 (fr) | 2008-07-30 | 2011-05-11 | Msd K.K. | Dérivé de cycloalkylamine à noyaux fusionnés à (5 chaînons)-(5 chaînons) ou (5 chaînons) (6 chaînons) |
CN102838589B (zh) * | 2008-09-23 | 2014-03-26 | 成都地奥制药集团有限公司 | 经甲磺酰化的制备n取代的吡咯烷衍生物的方法 |
US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
KR101320245B1 (ko) | 2008-10-30 | 2013-10-30 | 머크 샤프 앤드 돔 코포레이션 | 이소니코틴아미드 오렉신 수용체 길항제 |
CA2741672A1 (fr) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Nouveaux agents antidiabetiques utiles avec des derives de benzimidazole cycliques |
AU2009314200B2 (en) | 2008-11-17 | 2011-11-17 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
CA2768577A1 (fr) | 2009-07-23 | 2011-01-27 | Schering Corporation | Composes d?oxazepine benzofusionnes en tant qu?inhibiteurs de la coenzyme-stearoyle a delta-9 desaturase |
WO2011011506A1 (fr) | 2009-07-23 | 2011-01-27 | Schering Corporation | Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase |
EP2475428B1 (fr) | 2009-09-11 | 2015-07-01 | Probiodrug AG | Dérivés hétérocycliques en tant qu'inhibiteurs de glutaminyle cyclase |
AU2010317842A1 (en) | 2009-11-16 | 2012-07-12 | Mellitech | [1,5]-diazocin derivatives |
US8648073B2 (en) | 2009-12-30 | 2014-02-11 | Fochon Pharma, Inc. | Certain dipeptidyl peptidase inhibitors |
CA2786314A1 (fr) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Nouveaux derives benzimidazole cycliques utiles comme agents antidiabetiques |
WO2011107530A2 (fr) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Nouveaux inhibiteurs |
CA2789440C (fr) | 2010-03-10 | 2020-03-24 | Probiodrug Ag | Inhibiteurs heterocycliques de la glutaminyl cyclase (qc, ec 2.3.2.5) |
WO2011127051A1 (fr) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur de gpr119 et traitement de troubles associés |
JP5945532B2 (ja) | 2010-04-21 | 2016-07-05 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
EA201390421A1 (ru) | 2010-09-22 | 2013-09-30 | Арена Фармасьютикалз, Инк. | Модуляторы рецептора gpr119 и лечение связанных с ним нарушений |
CA2826649C (fr) | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Nouveaux derives d'azabenzimidazole cyclique utiles en tant qu'agents antidiabetiques |
EP2681236B1 (fr) | 2011-03-01 | 2018-01-03 | Synergy Pharmaceuticals Inc. | Procédé de préparation d'agonistes du guanylate cyclase c |
ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140051714A1 (en) | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012170702A1 (fr) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci |
WO2013055910A1 (fr) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles associés |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2014074668A1 (fr) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulateurs de gpr119 et traitement de troubles associés à ceux-ci |
EP2958562A4 (fr) | 2013-02-22 | 2016-08-10 | Merck Sharp & Dohme | Composés bicycliques antidiabétiques |
WO2014139388A1 (fr) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques |
JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
JP2016514670A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト |
BR112015030326A2 (pt) | 2013-06-05 | 2017-08-29 | Synergy Pharmaceuticals Inc | Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos |
WO2015051496A1 (fr) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
BR112017003745A2 (pt) | 2014-08-29 | 2017-12-05 | Tes Pharma S R L | inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico |
BR112017017719A2 (pt) | 2015-02-20 | 2018-04-10 | Idexx Lab Inc | imunoensaio homogêneo com compensação para sinal antecedente |
KR20220070057A (ko) | 2015-03-09 | 2022-05-27 | 인테크린 테라퓨틱스, 아이엔씨. | 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법 |
CN109952292A (zh) | 2016-10-14 | 2019-06-28 | Tes制药有限责任公司 | α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂 |
EP3551176A4 (fr) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Composés hétérocycliques antidiabétiques |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
WO2018162722A1 (fr) | 2017-03-09 | 2018-09-13 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Inhibiteurs de dpp-4 à utiliser dans le traitement de fractures osseuses |
MX2019011867A (es) | 2017-04-03 | 2020-01-09 | Coherus Biosciences Inc | Agonista de ppary para el tratamiento de la paralisis supranuclear progresiva. |
ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
CA3079011A1 (fr) | 2017-10-19 | 2019-04-25 | Idexx Laboratories, Inc. | Detection de dimethylarginine symetrique |
BR112021009589A2 (pt) | 2018-11-20 | 2021-08-17 | Tes Pharma S.R.L. | inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico |
WO2020167706A1 (fr) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | Agonistes du récepteur de l'orexine 5-alkyl-pyrrolidine |
EP4010314B1 (fr) | 2019-08-08 | 2024-02-28 | Merck Sharp & Dohme LLC | Agonistes du récepteur de l'orexine de type pyrrolidine et pipéridine hétéroaryle |
BR112023002957A2 (pt) | 2020-08-18 | 2023-04-04 | Merck Sharp & Dohme Llc | Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL111785A0 (en) * | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
US6090786A (en) * | 1994-06-10 | 2000-07-18 | Fondatech Benelux N.V. | Serine proteases, their activity and their synthetic inhibitors |
GB9504350D0 (en) * | 1995-03-04 | 1995-04-26 | Sod Conseils Rech Applic | Arginine derivatives |
-
2001
- 2001-05-15 FR FR0106375A patent/FR2824825B1/fr not_active Expired - Fee Related
-
2002
- 2002-05-08 JP JP2002132484A patent/JP3798337B2/ja not_active Expired - Fee Related
- 2002-05-09 MX MXPA02004642A patent/MXPA02004642A/es active IP Right Grant
- 2002-05-10 CA CA002383298A patent/CA2383298C/fr not_active Expired - Fee Related
- 2002-05-14 NO NO20022285A patent/NO322569B1/no unknown
- 2002-05-14 BR BR0201697-4A patent/BR0201697A/pt not_active IP Right Cessation
- 2002-05-14 NZ NZ518948A patent/NZ518948A/en unknown
- 2002-05-14 HU HU0201646A patent/HUP0201646A3/hu unknown
- 2002-05-14 AR ARP020101750A patent/AR033735A1/es unknown
- 2002-05-14 DK DK02291192T patent/DK1258476T3/da active
- 2002-05-14 EA EA200200446A patent/EA004865B1/ru not_active IP Right Cessation
- 2002-05-14 DE DE60212759T patent/DE60212759T2/de not_active Expired - Fee Related
- 2002-05-14 SI SI200230350T patent/SI1258476T1/sl unknown
- 2002-05-14 ES ES02291192T patent/ES2266422T3/es not_active Expired - Lifetime
- 2002-05-14 PT PT02291192T patent/PT1258476E/pt unknown
- 2002-05-14 AT AT02291192T patent/ATE331705T1/de not_active IP Right Cessation
- 2002-05-14 EP EP02291192A patent/EP1258476B1/fr not_active Expired - Lifetime
- 2002-05-15 KR KR10-2002-0026768A patent/KR100460782B1/ko not_active IP Right Cessation
- 2002-05-15 US US10/146,272 patent/US6706742B2/en not_active Expired - Fee Related
- 2002-05-15 CN CNB021199027A patent/CN1164573C/zh not_active Expired - Fee Related
- 2002-05-15 AU AU40654/02A patent/AU780480B2/en not_active Ceased
- 2002-05-15 ZA ZA200203867A patent/ZA200203867B/xx unknown
- 2002-05-15 PL PL02353910A patent/PL353910A1/xx not_active Application Discontinuation
-
2003
- 2003-04-10 HK HK03102618A patent/HK1050526A1/xx not_active IP Right Cessation
-
2006
- 2006-09-27 CY CY20061101393T patent/CY1105385T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2383298A1 (fr) | Nouveaux derives d'.alpha.-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
CA2379197A1 (fr) | Nouveaux derives sulfonyles d'.alpha.-amino acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
ATE287408T1 (de) | Tricyclische derivate der pyrazolcarbonsäure, ihre herstellung und sie enthaltende pharmazeutische zubereitungen | |
ATE469136T1 (de) | Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1 | |
MA27129A1 (fr) | Les pyrrolopyrimidines en tant qu'inhibiteurs du kinase de proteine. | |
EA200400480A1 (ru) | N-замещённые производные пирролидина в качестве ингибиторов дипептидилпептидазы | |
DK1004578T3 (da) | 5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater | |
EA200201271A1 (ru) | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 | |
BRPI0414514A (pt) | uso de um composto, composto, e, composições farmacêuticas | |
WO2003057225A3 (fr) | Inhibiteurs de transport du phosphate | |
MA27654A1 (fr) | DERIVES HEXAHYDROPYRAZINO [1,2-a]-4,7-DIONE SUBSTITUES, METHODE POUR LEUR PRODUCTION ET LEUR UTILISATION EN TANT QUE MEDICAMENTS | |
MA27560A1 (fr) | Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation | |
ATE245152T1 (de) | Dioxocyclopentylhydroxamsäure | |
MA28286A1 (fr) | Dérivés de 1-N-phenyl-amino-1H-imidazole et compositions pharmaceutiques les contenant | |
BR0210392A (pt) | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto | |
EA200400708A1 (ru) | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 | |
MA27576A1 (fr) | Nouveaux derives d'azepines tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
CA2332513A1 (fr) | Nouveaux derives de 4-sulfonamides piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
CA2216664A1 (fr) | Nouvelles amines cycliques n-substituees, leur procede de preparation et les compositions pharmaceutiques les renfermant | |
ATE440838T1 (de) | Pharmazeutisch aktive sulfonylaminosäurederivate | |
BR0213327A (pt) | Derivados de 4-fenil-4-[1h-imidazol-2-il]-piperidina substituìdos e sua aplicação como agonistas de delta opióides não-peptìdicos seletivos | |
CA2364864A1 (fr) | Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions phamaceutiques qui les contiennent | |
EA200400707A1 (ru) | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 | |
CA2326710A1 (fr) | Nouveaux derives de dihydrofuro-¬3,4-b|quinolein-1-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
CA2313302A1 (fr) | Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |